Recently, both the manufacturer of citalopram and the US Food and Drug Administration
have warned health care providers and patients about new information implicating drug-
induced QTc interval prolongation and torsade de pointes when using citalopram in doses>
40 mg/day. This warning is not placed in the context of either benefits or risks in real-world
clinical practice, leaving clinicians with an untenable choice between depriving patients of
high-dose citalopram or malpractice litigation. We reviewed the literature and found no …